WuXi Biologics

WuXi Biologics was founded with a vision to transform the pharmaceutical industry by providing open-access, integrated technology platforms. The company was established by Dr. Ge Li, who also founded WuXi AppTec, a leading pharmaceutical, biopharmaceutical, and medical device outsourcing company. WuXi Biologics emerged as a separate entity to focus on biologics, which are complex molecules used in drug development.

The company quickly gained traction by offering end-to-end solutions for biologics discovery, development, and manufacturing. This approach allowed pharmaceutical companies to accelerate their drug development processes, reduce costs, and improve efficiency. WuXi Biologics' commitment to quality and innovation helped it build a strong reputation in the biotech industry.

A significant milestone in WuXi Biologics' journey was its Initial Public Offering (IPO) on the Hong Kong Stock Exchange in 2017. The IPO was a resounding success, raising substantial capital that fueled the company's expansion plans. This event marked WuXi Biologics as a major player in the global biotech landscape.

Since its IPO, WuXi Biologics has continued to grow, expanding its capabilities and geographic reach. The company has established state-of-the-art facilities in multiple countries, enabling it to serve a diverse clientele worldwide. WuXi Biologics' growth trajectory underscores its role as a key enabler in the development of life-saving biologics, making it an indispensable partner for pharmaceutical companies around the globe.